Evidence map›Paper›PMID 24896636›Full record

ArticlePloS one2014

Glutathione metabolism in Candida albicans resistant strains to fluconazole and micafungin.

Bruno Maras, Letizia Angiolella, Giuseppina Mignogna, Elisabetta Vavala, Alberto Macone, Marisa Colone, Giuseppina Pitari, Annarita Stringaro, Silvestro Dupré, Anna Teresa Palamara

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Anticandidal Activity of a Siderophore from Marine EndophyteAntibiotics (Basel, Switzerland) · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Nine Things Genomics Can Tell Us AboutFrontiers in genetics · 2020
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Bruno MarasDipartimento di Scienze Biochimiche "A. Rossi Fanelli", Sapienza Università di Roma, Rome, Italy.
Letizia AngiolellaDipartimento di Sanità Pubblica e Malattie Infettive, Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza Università di Roma, Rome, Italy.
Giuseppina MignognaDipartimento di Scienze Biochimiche "A. Rossi Fanelli", Sapienza Università di Roma, Rome, Italy.
Elisabetta VavalaDipartimento di Sanità Pubblica e Malattie Infettive, Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza Università di Roma, Rome, Italy.
Alberto MaconeDipartimento di Scienze Biochimiche "A. Rossi Fanelli", Sapienza Università di Roma, Rome, Italy.
Marisa ColoneDipartimento di Tecnologie e Salute, Istituto Superiore di Sanità, Rome, Italy.
Giuseppina PitariDipartimento di Biologia di Base ed Applicata, Università degli Studi L'Aquila, L'Aquila, Italy.
Annarita StringaroDipartimento di Tecnologie e Salute, Istituto Superiore di Sanità, Rome, Italy.
Silvestro DupréDipartimento di Scienze Biochimiche "A. Rossi Fanelli", Sapienza Università di Roma, Rome, Italy.
Anna Teresa PalamaraDipartimento di Sanità Pubblica e Malattie Infettive, Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza Università di Roma, Rome, Italy.
Sapienza University of Rome · ITIstituto Pasteur · ITIstituto Superiore di Sanità · ITUniversity of L'Aquila · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently available therapies for candidiasis are based on antifungal drugs belonging to azole and echinocandin families that interfere with different aspects of fungal metabolism. These drugs, beyond their specific effects, elicit also a cellular stress including an unbalance of redox state that is counteracted not only utilizing antioxidant species but also increasing the outcome export by transporters to detoxify the internal environment. These cellular actions are both based on the cytosolic concentration of reduced glutathione (GSH). In this paper we investigated the effects of two antifungal drugs fluconazole and micafungin on the redox state of the cell in C. albicans to understand if the resistance to these drugs is accompanied by variation of glutathione metabolism. Analyses of resistant strains showed a marked difference in glutathione contents in strains resistant to fluconazole (CO23RFLC) or micafungin (CO23RFK). In CO23RFLC, the total amount of glutathione was more than doubled with respect to CO23RFK thanks to the increased activity of γ-glutamilcysteine synthetase, the key enzyme involved in GSH synthesis. We demonstrated that the GSH increase in CO23RFLC conferred to this strain a clear advantage in counteracting oxidative toxic agents while assignment of other roles, such as a more efficient elimination of the drug from the cell, should be considered more speculative. As far as MCFG resistance is concerned, from our data a role of glutathione metabolism in supporting this condition is not evident. Overall our data indicate that glutathione metabolism is differently affected in the two resistant strains and that glutathione system may play an important role in the global organization of C.albicans cells for resistance to fluconazole. Such scenario may pave the way to hypothesize the use of oxidant drugs or inhibitors able to deplete reduced glutathione level as a novel approach, for counteracting the resistance to this specific antifungal drug.

Indexed as

Antifungal AgentsCandida albicansCandidiasisDrug Resistance, FungalEchinocandinsFluconazoleGlutathioneLipopeptidesMicafunginMicrobial Sensitivity TestsOxidation-ReductionAntifungal AgentsEchinocandinsFluconazoleGlutathioneLipopeptidesMicafungin

Identifiers

PMID24896636
PMCPMC4045664
OpenAlexW1979114598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.